Press Releases

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 18, 2024

Read More

BioCryst to Present at Upcoming Investor Conferences

Nov 06, 2024

Read More

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 05, 2024

Read More

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 04, 2024

Read More

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

Oct 24, 2024

Read More

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 21, 2024

Read More

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 14, 2024

Read More

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

Oct 10, 2024

Read More

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 03, 2024

Read More

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Oct 02, 2024

Read More